• Intuitive Surgical recently drew attention ahead of its past earnings release, with analysts expecting quarterly earnings of US$2.08 per share and revenue of US$2.61 billion, both higher than the year-ago period.
• A recent upward revision in the consensus earnings estimate, albeit modest, highlights how analysts have been reassessing Intuitive Surgical’s near-term performance expectations.
• Now, we’ll examine how the recent upward revision in quarterly earnings expectations could influence Intuitive Surgical’s broader investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Intuitive Surgical Investment Narrative Recap

To own Intuitive Surgical, you generally have to believe that robotic assisted surgery will keep gaining share across more procedures and geographies, supported by an expanding installed base and recurring instrument revenue. The recent uptick in consensus EPS for the coming quarter is modest, so it does not materially change the core near term catalyst, which is continued procedure growth on the da Vinci and Ion platforms, or the biggest current risk around cost and reimbursement pressure on hospitals.

One of the most relevant recent developments here is the FDA clearance of the da Vinci 5 system for select cardiac procedures, which broadens its clinical footprint beyond core urology and general surgery. This kind of label expansion matters because it can support higher utilization of existing systems and future upgrade cycles, linking directly to the earnings expectations analysts have just revised upward, even as regulatory and hospital budget headwinds remain key watchpoints.

Yet while procedure growth and new approvals are encouraging, investors should also consider how rising healthcare cost scrutiny could eventually affect pricing and utilization...

Intuitive Surgical's narrative projects $13.4 billion revenue and $3.7 billion earnings by 2028. This requires 13.5% yearly revenue growth and about a $1.1 billion earnings increase from $2.6 billion today.

Uncover how Intuitive Surgical's forecasts yield a $611.82 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already assuming only about 10.6 percent annual revenue growth to roughly US$13.6 billion by 2029 and see heightened pricing pressure as a core risk, so this latest earnings revision may either soften or reinforce that more pessimistic view depending on how you think hospital budgets and reimbursement trends evolve from here.

Explore 15 other fair value estimates on Intuitive Surgical - why the stock might be worth as much as 60% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intuitive Surgical's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.